Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to NanoDoce

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04060628
Expanded Access Status : Available
First Posted : August 19, 2019
Last Update Posted : September 9, 2020
Sponsor:
Collaborator:
US Biotest, Inc.
Information provided by (Responsible Party):
NanOlogy, LLC

Brief Summary:
NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.

Condition or disease Intervention/treatment
Urogenital Neoplasms Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access to NanoDoce

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel


Intervention Details:
  • Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
    Other Name: docetaxel

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04060628


Contacts
Layout table for location contacts
Contact: Gere diZerega, MD 805-595-1300 gere.dizerega@usbiotest.com

Sponsors and Collaborators
NanOlogy, LLC
US Biotest, Inc.
Layout table for additonal information
Responsible Party: NanOlogy, LLC
ClinicalTrials.gov Identifier: NCT04060628    
Other Study ID Numbers: NANODOCE-EA
First Posted: August 19, 2019    Key Record Dates
Last Update Posted: September 9, 2020
Last Verified: September 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action